Skip to main content
ALURD logo

ALURD · Allurion Technologies, Inc.

$4.36 -0.19 (-4.18%) At close · Jul 29
Market Cap
$68.28M
Shares
15.01M

Allurion Technologies, Inc. Earnings Call Transcripts

Every quarterly earnings call for Allurion Technologies, Inc. (ALURD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q3
2025-11-12
Allurion Technologies, Inc. Q3 FY2025 Earnings Call
Confident tone Strategic pivot to combination therapy with GLP-1s U.S. market launch preparation FDA approval progress
Revenue
$2.66M
▼ 50.5% YoY
Diluted EPS
$-22.95
▼ 145% YoY
Gross margin
49.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allurion Technologies, Inc. Q2 FY2025 Earnings Call
Positive tone R&D pipeline and GLP-1 drug-eluting balloon Strategic pivot to combination therapy with low-dose GLP-1s Operating expense reduction and restructuring
Revenue
$3.38M
▼ 71.3% YoY
Diluted EPS
$-19.20
Gross margin
73.9%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-14
Allurion Technologies, Inc. Q1 FY2025 Earnings Call
Confident tone GLP-1 Combination Strategy FDA Approval Pathway Path to Profitability
Revenue
$5.58M
▼ 40.5% YoY
Diluted EPS
$-4.65
▼ 132.3% YoY
Gross margin
74.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
Allurion Technologies, Inc. Q4 FY2024 Earnings Call
Revenue
$5.59M*
Gross margin
45.3%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2025-03-03
TD Cowen's 45th Annual Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY24 · Q3
2024-11-13
Allurion Technologies, Inc. Q3 FY2024 Earnings Call
Positive tone Q3 Financial Results and France Recall GLP-1 Market Impact and Combination Therapy U.S. FDA Approval and Launch
Revenue
$5.37M
▼ 70.5% YoY
Diluted EPS
$51.00
Gross margin
58.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Allurion Technologies, Inc. Q2 FY2024 Earnings Call
Balanced tone France ANSM suspension GLP-1 competition and positioning Procedure volume and demand
Revenue
$11.77M
▼ 9.2% YoY
Diluted EPS
$-65.10
Gross margin
76.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Allurion Technologies, Inc. Q1 FY2024 Earnings Call
Confident tone Revenue and 2024 guidance Virtual Care Suite / B2B SaaS Geographic expansion and AUDACITY FDA trial
Revenue
$9.39M
Diluted EPS
$14.40
Gross margin
73.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Allurion Technologies, Inc. Q4 FY2023 Earnings Call
Positive tone GLP-1 drugs as opportunity and headwind Cost reduction and cash burn Audacity FDA trial and PMA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Allurion Technologies, Inc. Q3 FY2023 Earnings Call
Revenue
$18.20M
Diluted EPS
$-202.50
Gross margin
76.7%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1964979 CUSIP 02008G300 13F (30d) 1 filings 1 filers Visit website